Together, the introduction of sgp130Fc therapeutics for the treatment of IL-6-driven chronic inflammatory diseases may contribute to TB prevention by providing a lower risk of disease reactivation as one of the major adverse effects of cytokine-directed immunosuppressive therapy. This evidence concerns the gene IL6 and tuberculosis.